BioSpace News Archive

Pharmaron Beijing Co., Ltd. announced that 117 million H-shares are listed on the Main Board of The Stock Exchange of Hong Kong.

Genetron Health, a China-based precision oncology company that covers full-cycle cancer care, has obtained regulatory approval in China to launch its GENETRON S5 for clinical use.

The agreement with the Bill & Melinda Gates Foundation provides that MedinCell owns the marketing rights of the product worldwide, particularly in the United States.

Liminal BioSciences Inc. acknowledges the press release issued by the Autorité des Marchés Financiers in which the AMF announced that after a thorough investigation, the AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019.

Ascletis Pharma Inc. announces that Ascletis XinNuo Medicine Co.,Ltd., a wholly-owned subsidiary of Ascletis, has recently obtained the Pharmaceutical Trade License and GSP Certificate issued by ZheJiang Medical Products Administration.

MedMira Inc., reported on its financial results for the financial year ended July 31, 2019.

Satralizumab added to baseline immunosuppressant therapy significantly reduced risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).

Submission follows completion of a Clinical Endpoint study

Recipharm announced today ongoing large-scale commercial manufacturing of RedHill Biopharma’s (Nasdaq: RDHL) drug, Talicia® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg[1]/250 mg/12.5 mg, for its planned launch in the first quarter 2020.